
HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use warfarin sodium safely and effectively. See full prescribing information for warfarin sodium. Warfarin Sodium Tablets USP, for oral use

Initial U.S. Approval: 1954

WARNING: BLEEDING RISK

See full prescribing information for complete boxed warning.

- Warfarin sodium can cause major or fatal bleeding. (5.1)
- Perform regular monitoring of INR in all treated patients. (2.1)
- Drugs, dietary changes, and other factors affect INR levels achieved with warfarin sodium therapy. (7)
- Instruct patients about prevention measures to minimize risk of bleeding and to report signs and symptoms of bleeding. (17)

----- RECENT MAJOR CHANGES ------

Contraindications (4)	10/2011
Warnings and Precautions, Use in Pregnant Women with Mechanical Heart Valves (5.5)	10/2011

------ INDICATIONS AND USAGE

Warfarin sodium is a vitamin K antagonist indicated for:

- Prophylaxis and treatment of venous thrombosis and its extension, pulmonary embolism (1)
- Prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement (1)
- Reduction in the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction (1)

Limitation of Use

Warfarin sodium has no direct effect on an established thrombus, nor does it reverse ischemic tissue damage. (1)

- ----- DOSAGE AND ADMINISTRATION ------
- Individualize dosing regimen for each patient, and adjust based on INR response. (2.1, 2.2)
- Knowledge of genotype can inform initial dose selection. (2.3)
- Monitoring: Obtain daily INR determinations upon initiation until stable in the therapeutic range. Obtain subsequent INR determinations every 1 to 4 weeks. (2.4)
- Review conversion instructions from other anticoagulants. (2.8)

DOSAGE FORMS AND STRENGTHS

• Scored tablets: 1, 2, 2-1/2, 3, 4, 5, 6, 7-1/2, or 10 mg (3)

----- CONTRAINDICATIONS ------

- Pregnancy, except in women with mechanical heart valves (4)
- Hemorrhagic tendencies or blood dyscrasias (4)
- Recent or contemplated surgery of the central nervous system (CNS) or eye, or traumatic surgery resulting in large open surfaces (4, 5.7)
- Bleeding tendencies associated with certain conditions (4)
- Threatened abortion, eclampsia, and preeclampsia (4)
- Unsupervised patients with potential high levels of non-compliance (4)
- Spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding (4)
- Hypersensitivity to warfarin or any component of the product (4)
- Major regional or lumbar block anesthesia (4)
- Malignant hypertension (4)

WARNINGS AND PRECAUTIONS Tissue necrosis: Necrosis or gangrene of skin or other tissues can occur, with severe	
amputation. Discontinue warfarin sodium and consider alternative anticoagulants if ne	
• Systemic atheroemboli and cholesterol microemboli: Some cases have progressed t warfarin sodium if such emboli occur. (5.3)	
• Heparin-induced thrombocytopenia (HIT): Initial therapy with warfarin sodium in HIT	
amputation and death. Warfarin sodium may be considered after platelet count has no	
• Pregnant women with mechanical heart valves: Warfarin sodium may cause fetal harmoutweigh the risks. (5.5)	m; however, the benefits may
ADVERSE REACTIONS	
Most common adverse reactions to warfarin sodium are fatal and nonfatal hemorrhage f	rom any tissue or organ. (6)
To report SUSPECTED ADVERSE REACTIONS, contact FDA at 1-800-FDA-108	9 or your fda gov/medwatch
DRUG INTERACTIONS	
conour moemig of an concurrently abea arago for complete miormation about meeta	
	ctions with warfarin sodium or
 Consult labeling of all concurrently used drugs for complete information about intera increased risks for bleeding. (7) Inhibitors and inducers of CYP2C9, 1A2, or 3A4: May alter warfarin exposure. Monit 	actions with warfarin sodium or for INR closely when any such drug (e.g., other anticoagulants,
 Consult labeling of all concurrently used drugs for complete information about intera increased risks for bleeding. (7) Inhibitors and inducers of CYP2C9, 1A2, or 3A4: May alter warfarin exposure. Monit is used with warfarin sodium. (7.1) Drugs that increase bleeding risk: Closely monitor patients receiving any such drug (actions with warfarin sodium or for INR closely when any such drug (e.g., other anticoagulants, ars). (7.2)

• Nursing mothers: Use with caution in a nursing woman. Monitor breast-feeding infants for bruising or bleeding. (8.3)

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.

Revised: 11/2011

FULL PRESCRIBING INFORMATION: CONTENTS* WARNING: BLEEDING RISK 1 INDICATIONS AND USAGE

2 DOSAGE AND ADMINISTRATION

- 2.1 Individualized Dosing
- 2.2 Recommended Target INR Ranges and Durations for Individual Indications
- 2.3 Initial and Maintenance Dosing
- 2.4 Monitoring to Achieve Optimal Anticoagulation
- 2.5 Missed Dose
- 2.7 Treatment During Dentistry and Surgery
- 2.8 Conversion From Other Anticoagulants

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

- 5.1 Hemorrhage
- 5.2 Tissue Necrosis
- 5.3 Systemic Atheroemboli and Cholesterol Microemboli
- 5.4 Heparin-Induced Thrombocytopenia
- 5.5 Use in Pregnant Women with Mechanical Heart Valves
- 5.6 Females of Reproductive Potential
- 5.7 Other Clinical Settings with Increased Risks
- 5.8 Endogenous Factors Affecting INR

6 ADVERSE REACTIONS

7 DRUG INTERACTIONS

- 7.1 CYP450 Interactions
- 7.2 Drugs that Increase Bleeding Risk
- 7.3 Antibiotics and Antifungals
- 7.4 Botanical (Herbal) Products and Foods

8 USE IN SPECIFIC POPULATIONS

- 8.1 Pregnancy
- 8.3 Nursing Mothers
- 8.4 Pediatric Use
- 8.5 Geriatric Use
- 8.6 Renal Impairment
- 8.7 Hepatic Impairment
- 8.8 Females of Reproductive Potential

10 OVERDOSAGE

- 10.1 Signs and Symptoms
- 10.2 Treatment

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

- 12.1 Mechanism of Action
- 12.2 Pharmacodynamics
- 12.3 Pharmacokinetics
- 12.5 Pharmacogenomics

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

14 CLINICAL STUDIES

- 14.1 Atrial Fibrillation
- 14.2 Mechanical and Bioprosthetic Heart Valves
- 14.3 Myocardial Infarction

15 REFERENCES

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

* Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

WARNING: BLEEDING RISK

- Warfarin sodium can cause major or fatal bleeding [see *Warnings and Precautions (5.1)*].
- Perform regular monitoring of INR in all treated patients [see *Dosage and Administration* (2.1)].
- Drugs, dietary changes, and other factors affect INR levels achieved with warfarin sodium therapy [see *Drug Interactions (7)*].
- Instruct patients about prevention measures to minimize risk of bleeding and to report signs and symptoms of bleeding [see *Patient Counseling Information (17)*].

1 INDICATIONS AND USAGE

Warfarin sodium tablets, USP are indicated for:

- Prophylaxis and treatment of venous thrombosis and its extension, pulmonary embolism (PE).
- Prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation (AF) and/or cardiac valve replacement.
- Reduction in the risk of death, recurrent myocardial infarction (MI), and thromboembolic events such as stroke or systemic embolization after myocardial infarction.

Limitations of Use

Warfarin sodium has no direct effect on an established thrombus, nor does it reverse ischemic tissue damage. Once a thrombus has occurred, however, the goals of anticoagulant treatment are to prevent further extension of the formed clot and to prevent secondary thromboembolic complications that may result in serious and possibly fatal sequelae.

2 DOSAGE AND ADMINISTRATION

2.1 Individualized Dosing

The dosage and administration of warfarin sodium must be individualized for each patient according to the patient's INR response to the drug. Adjust the dose based on the patient's INR and the condition being treated. Consult the latest evidence-based clinical practice guidelines from the American College of Chest Physicians (ACCP) to assist in the determination of the duration and intensity of anticoagulation with warfarin sodium [see *References (15)*].

2.2 Recommended Target INR Ranges and Durations for Individual Indications

An INR of greater than 4.0 appears to provide no additional therapeutic benefit in most patients and is associated with a higher risk of bleeding.

Venous Thromboembolism (including deep venous thrombosis [DVT] and PE)

Adjust the warfarin dose to maintain a target INR of 2.5 (INR range, 2.0-3.0) for all treatment durations. The duration of treatment is based on the indication as follows:

- For patients with a DVT or PE secondary to a transient (reversible) risk factor, treatment with warfarin for 3 months is recommended.
- For patients with an unprovoked DVT or PE, treatment with warfarin is recommended for at least 3 months. After 3 months of therapy, evaluate the risk-benefit ratio of long-term treatment for the individual patient.
- For patients with two episodes of unprovoked DVT or PE, long-term treatment with warfarin is recommended. For a patient receiving long-term anticoagulant treatment, periodically reassess the risk-benefit ratio of continuing such treatment in the individual patient.

Atrial Fibrillation

In patients with non-valvular AF, anticoagulate with warfarin to target INR of 2.5 (range, 2.0-3.0).

- In patients with non-valvular AF that is persistent or paroxysmal and at high risk of stroke (i.e., having any of the following features: prior ischemic stroke, transient ischemic attack, or systemic embolism, or 2 of the following risk factors: age greater than 75 years, moderately or severely impaired left ventricular systolic function and/or heart failure, history of hypertension, or diabetes mellitus), long-term anticoagulation with warfarin is recommended.
- In patients with non-valvular AF that is persistent or paroxysmal and at an intermediate risk of ischemic stroke (i.e., having 1 of the following risk factors: age greater than 75 years, moderately or severely impaired left ventricular systolic function and/or heart failure, history of hypertension, or diabetes mellitus), long-term anticoagulation with warfarin is recommended.
- For patients with AF and mitral stenosis, long-term anticoagulation with warfarin is recommended.
- For patients with AF and prosthetic heart valves, long-term anticoagulation with warfarin is recommended; the target INR may be increased and aspirin added depending on valve type and

position, and on patient factors.

Mechanical and Bioprosthetic Heart Valves

- For patients with a bileaflet mechanical valve or a Medtronic Hall (Minneapolis, MN) tilting disk valve in the aortic position who are in sinus rhythm and without left atrial enlargement, therapy with warfarin to a target INR of 2.5 (range, 2.0-3.0) is recommended.
- For patients with tilting disk valves and bileaflet mechanical valves in the mitral position, therapy with warfarin to a target INR of 3.0 (range, 2.5-3.5) is recommended.
- For patients with caged ball or caged disk valves, therapy with warfarin to a target INR of 3.0 (range, 2.5-3.5) is recommended.
- For patients with a bioprosthetic valve in the mitral position, therapy with warfarin to a target INR of 2.5 (range, 2.0-3.0) for the first 3 months after valve insertion is recommended. If additional risk factors for thromboembolism are present (AF, previous thromboembolism, left ventricular dysfunction), a target INR of 2.5 (range, 2.0-3.0) is recommended.

Post-Myocardial Infarction

• For high-risk patients with MI (e.g., those with a large anterior MI, those with significant heart failure, those with intracardiac thrombus visible on transthoracic echocardiography, those with AF, and those with a history of a thromboembolic event), therapy with combined moderate-intensity (INR, 2.0-3.0) warfarin plus low-dose aspirin (≤100 mg/day) for at least 3 months after the MI is recommended.

Recurrent Systemic Embolism and Other Indications

Oral anticoagulation therapy with warfarin has not been fully evaluated by clinical trials in patients with valvular disease associated with AF, patients with mitral stenosis, and patients with recurrent systemic embolism of unknown etiology. However, a moderate dose regimen (INR 2.0-3.0) may be used for these patients.

2.3 Initial and Maintenance Dosing

The appropriate initial dosing of warfarin sodium varies widely for different patients. Not all factors responsible for warfarin dose variability are known, and the initial dose is influenced by:

- Clinical factors including age, race, body weight, sex, concomitant medications, and comorbidities
- Genetic factors (CYP2C9 and VKORC1 genotypes) [see *Clinical Pharmacology* (12.5)]

Select the initial dose based on the expected maintenance dose, taking into account the above factors. Modify this dose based on consideration of patient-specific clinical factors. Consider lower initial and maintenance doses for elderly and/or debilitated patients and in Asian patients [see *Use in Specific Populations (8.5)* and *Clinical Pharmacology (12.3)*]. Routine use of loading doses is not recommended as this practice may increase hemorrhagic and other complications and does not offer more rapid protection against clot formation.

Individualize the duration of therapy for each patient. In general, anticoagulant therapy should be continued until the danger of thrombosis and embolism has passed [see *Dosage and Administration (2.2)*].

Dosing Recommendations without Consideration of Genotype

If the patient's CYP2C9 and VKORC1 genotypes are not known, the initial dose of warfarin sodium is usually 2 to 5 mg once daily. Determine each patient's dosing needs by close monitoring of the INR response and consideration of the indication being treated. Typical maintenance doses are 2 to 10 mg once daily.

Dosing Recommendations with Consideration of Genotype

Table 1 displays three ranges of expected maintenance warfarin sodium doses observed in subgroups of patients having different combinations of CYP2C9 and VKORC1 gene variants [see *Clinical*

Pharmacology (12.5)]. If the patient's CYP2C9 and/or VKORC1 genotype are known, consider these ranges in choosing the initial dose. Patients with CYP2C9 *1/*3, *2/*2, *2/*3, and *3/*3 may require more prolonged time (>2 to 4 weeks) to achieve maximum INR effect for a given dosage regimen than patients without these CYP variants.

Table 1: Three Ranges of Expected Maintenance Warfarin Sodium Daily Doses Based
on CYP2C9 and VKORC1 Genotypes*

VKORC1	CYP2C9					
	*1/*1	*1/*2	*1/*3	*2/*2	*2/*3	*3/*3
GG	5-7 mg	5-7 mg	3-4 mg	3-4 mg	3-4 mg	0.5-2 mg
AG	5-7 mg	3-4 mg	3-4 mg	3-4 mg	0.5-2 mg	0.5-2 mg
AA	3-4 mg	3-4 mg	0.5-2 mg	0.5-2 mg	0.5-2 mg	0.5-2 mg

* Ranges are derived from multiple published clinical studies. VKORC1 –1639G>A (rs9923231) variant is used in this table. Other co-inherited VKORC1 variants may also be important determinants of warfarin dose.

2.4 Monitoring to Achieve Optimal Anticoagulation

Warfarin sodium is a narrow therapeutic range (index) drug, and its action may be affected by factors such as other drugs and dietary vitamin K. Therefore, anticoagulation must be carefully monitored during warfarin sodium therapy. Determine the INR daily after the administration of the initial dose until INR results stabilize in the therapeutic range. After stabilization, maintain dosing within the therapeutic range by performing periodic INRs. The frequency of performing INR should be based on the clinical situation but generally acceptable intervals for INR determinations are 1 to 4 weeks. Perform additional INR tests when other warfarin products are interchanged with warfarin sodium, as well as whenever other medications are initiated, discontinued, or taken irregularly. Heparin, a common concomitant drug, increases the INR [see *Dosage and Administration (2.8)* and *Drug Interactions (7)*].

Determinations of whole blood clotting and bleeding times are not effective measures for monitoring of warfarin sodium therapy.

2.5 Missed Dose

The anticoagulant effect of warfarin sodium persists beyond 24 hours. If a patient misses a dose of warfarin sodium at the intended time of day, the patient should take the dose as soon as possible on the same day. The patient should not double the dose the next day to make up for a missed dose.

2.7 Treatment During Dentistry and Surgery

Some dental or surgical procedures may necessitate the interruption or change in the dose of warfarin sodium therapy. Consider the benefits and risks when discontinuing warfarin sodium even for a short period of time. Determine the INR immediately prior to any dental or surgical procedure. In patients undergoing minimally invasive procedures who must be anticoagulated prior to, during, or immediately following these procedures, adjusting the dosage of warfarin sodium to maintain the INR at the low end of the therapeutic range may safely allow for continued anticoagulation.

2.8 Conversion From Other Anticoagulants

Heparin

Since the full anticoagulant effect of warfarin sodium is not achieved for several days, heparin is preferred for initial rapid anticoagulation. During initial therapy with warfarin sodium, the interference with heparin anticoagulation is of minimal clinical significance. Conversion to warfarin sodium may begin concomitantly with heparin therapy or may be delayed 3 to 6 days. To ensure therapeutic anticoagulation, continue full dose heparin therapy and overlap warfarin sodium therapy with heparin

for 4 to 5 days and until warfarin sodium has produced the desired therapeutic response as determined by INR, at which point heparin may be discontinued.

As heparin may affect the INR, patients receiving both heparin and warfarin sodium should have INR monitoring at least:

- 5 hours after the last intravenous bolus dose of heparin, or
- 4 hours after cessation of a continuous intravenous infusion of heparin, or
- 24 hours after the last subcutaneous heparin injection.

Warfarin sodium may increase the activated partial thromboplastin time (aPTT) test, even in the absence of heparin. A severe elevation (>50 seconds) in aPTT with an INR in the desired range has been identified as an indication of increased risk of postoperative hemorrhage.

Other Anticoagulants

Consult the labeling of other anticoagulants for instructions on conversion to warfarin sodium.

3 DOSAGE FORMS AND STRENGTHS

Warfarin Sodium Tablets, USP are single scored, engraved numerically with 1, 2, 2½, 3, 4, 5, 6, 7½, or 10 on one side, and engraved with "WARFARIN" on top of "TARO" on the other side.

Warfarin Sodium Tablets, USP are supplied in the following strengths:

Strength	Color
1 mg	pink
2 mg	lavender
2.5 mg	green
3 mg	tan
4 mg	blue
5 mg	peach
6 mg	teal
7.5 mg	yellow
10 mg	white (dye-free)

Warfarin Sodium Tablets, USP

4 CONTRAINDICATIONS

• Pregnancy

Warfarin sodium tablets, USP are contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [*see Warnings and Precautions* (5.5) and Use in Specific Populations (8.1)]. Warfarin sodium can cause fetal harm when administered to a pregnant woman. Warfarin sodium exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. If warfarin sodium is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Warnings and Precautions (5.6) and Use in Specific Populations (8.1)].

- Hemorrhagic tendencies or blood dyscrasias
- Recent or contemplated surgery of the central nervous system or eye, or traumatic surgery resulting in large open surfaces [*see Warnings and Precautions (5.7*)]
- Bleeding tendencies associated with:

- Active ulceration or overt bleeding of the gastrointestinal, genitourinary, or respiratory tract
- Central nervous system hemorrhage
- Cerebral aneurysms, dissecting aorta
- Pericarditis and pericardial effusions
- Bacterial endocarditis
- Threatened abortion, eclampsia, and preeclampsia
- Unsupervised patients with conditions associated with potential high level of non-compliance
- Spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding
- Hypersensitivity to warfarin or to any other components of this product (e.g., anaphylaxis) [see *Adverse Reactions* (6)]
- Major regional or lumbar block anesthesia
- Malignant hypertension

5 WARNINGS AND PRECAUTIONS

5.1 Hemorrhage

Warfarin sodium can cause major or fatal bleeding. Bleeding is more likely to occur within the first month. Risk factors for bleeding include high intensity of anticoagulation (INR >4.0), age greater than or equal to 65, history of highly variable INRs, history of gastrointestinal bleeding, hypertension, cerebrovascular disease, anemia, malignancy, trauma, renal impairment, certain genetic factors [see *Clinical Pharmacology (12.5)*], certain concomitant drugs [see *Drug Interactions (7)*], and long duration of warfarin therapy.

Perform regular monitoring of INR in all treated patients. Those at high risk of bleeding may benefit from more frequent INR monitoring, careful dose adjustment to desired INR, and a shortest duration of therapy appropriate for the clinical condition. However, maintenance of INR in the therapeutic range does not eliminate the risk of bleeding.

Drugs, dietary changes, and other factors affect INR levels achieved with warfarin sodium therapy. Perform more frequent INR monitoring when starting or stopping other drugs, including botanicals, or when changing dosages of other drugs [see *Drug Interactions (7)*]. Instruct patients about prevention measures to minimize risk of bleeding and to report signs and symptoms of bleeding [see *Patient Counseling Information (17)*].

5.2 Tissue Necrosis

Necrosis and/or gangrene of skin and other tissues is an uncommon but serious risk (<0.1%). Necrosis may be associated with local thrombosis and usually appears within a few days of the start of warfarin sodium therapy. In severe cases of necrosis, treatment through debridement or amputation of the affected tissue, limb, breast, or penis has been reported.

Careful clinical evaluation is required to determine whether necrosis is caused by an underlying disease. Although various treatments have been attempted, no treatment for necrosis has been considered uniformly effective. Discontinue warfarin sodium therapy if necrosis occurs. Consider alternative drugs if continued anticoagulation therapy is necessary.

5.3 Systemic Atheroemboli and Cholesterol Microemboli

Anticoagulation therapy with warfarin sodium may enhance the release of atheromatous plaque emboli. Systemic atheroemboli and cholesterol microemboli can present with a variety of signs and symptoms depending on the site of embolization. The most commonly involved visceral organs are the kidneys followed by the pancreas, spleen, and liver. Some cases have progressed to necrosis or death. A

distinct syndrome resulting from microemboli to the feet is known as "purple toes syndrome." Discontinue warfarin sodium therapy if such phenomena are observed. Consider alternative drugs if continued anticoagulation therapy is necessary.

5.4 Heparin-Induced Thrombocytopenia

Do not use warfarin sodium as initial therapy in patients with heparin-induced thrombocytopenia (HIT) and with heparin-induced thrombocytopenia with thrombosis syndrome (HITTS). Cases of limb ischemia, necrosis, and gangrene have occurred in patients with HIT and HITTS when heparin treatment was discontinued and warfarin therapy was started or continued. In some patients, sequelae have included amputation of the involved area and/or death. Treatment with warfarin sodium may be considered after the platelet count has normalized.

5.5 Use in Pregnant Women with Mechanical Heart Valves

Warfarin sodium can cause fetal harm when administered to a pregnant woman. While warfarin sodium is contraindicated during pregnancy, the potential benefits of using warfarin sodium may outweigh the risks for pregnant women with mechanical heart valves at high risk of thromboembolism. In those individual situations, the decision to initiate or continue warfarin sodium should be reviewed with the patient, taking into consideration the specific risks and benefits pertaining to the individual patient's medical situation, as well as the most current medical guidelines. Warfarin sodium exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see *Use in Specific Populations (8.1)*].

5.6 Females of Reproductive Potential

Warfarin sodium exposure during pregnancy can cause pregnancy loss, birth defects, or fetal death. Discuss pregnancy planning with females of reproductive potential who are on warfarin sodium therapy [see *Contraindications (4)* and *Use in Specific Populations (8.8)*].

5.7 Other Clinical Settings with Increased Risks

In the following clinical settings, the risks of warfarin sodium therapy may be increased:

- Moderate to severe hepatic impairment
- Infectious diseases or disturbances of intestinal flora (e.g., sprue, antibiotic therapy)
- Use of an indwelling catheter
- Severe to moderate hypertension
- Deficiency in protein C-mediated anticoagulant response: warfarin sodium reduces the synthesis of the naturally occurring anticoagulants, protein C and protein S. Hereditary or acquired deficiencies of protein C or its cofactor, protein S, have been associated with tissue necrosis following warfarin administration. Concomitant anticoagulation therapy with heparin for 5 to 7 days during initiation of therapy with warfarin sodium may minimize the incidence of tissue necrosis in these patients.
- Eye surgery: In cataract surgery, warfarin sodium use was associated with a significant increase in minor complications of sharp needle and local anesthesia block but not associated with potentially sight-threatening operative hemorrhagic complications. As warfarin sodium cessation or reduction may lead to serious thromboembolic complications, the decision to discontinue warfarin sodium before a relatively less invasive and complex eye surgery, such as lens surgery, should be based upon the risks of anticoagulant therapy weighed against the benefits.
- Polycythemia vera
- Vasculitis
- Diabetes mellitus

5.8 Endogenous Factors Affecting INR

The following factors may be responsible for **increased** INR response: diarrhea, hepatic disorders, poor nutritional state, steatorrhea, or vitamin K deficiency.

The following factors may be responsible for **decreased** INR response: increased vitamin K intake or hereditary warfarin resistance.

6 ADVERSE REACTIONS

The following serious adverse reactions to warfarin sodium are discussed in greater detail in other sections of the labeling:

- Hemorrhage [see Boxed Warning, Warnings and Precautions (5.1), and Overdosage (10)]
- Necrosis of skin and other tissues [see *Warnings and Precautions* (5.2)]
- Systemic atheroemboli and cholesterol microemboli [see *Warnings and Precautions (5.3)*]

Other adverse reactions to warfarin sodium include:

- Immune system disorders: hypersensitivity/allergic reactions (including urticaria and anaphylactic reactions)
- Vascular disorders: vasculitis
- Hepatobiliary disorders: hepatitis, elevated liver enzymes. Cholestatic hepatitis has been associated with concomitant administration of warfarin sodium and ticlopidine.
- Gastrointestinal disorders: nausea, vomiting, diarrhea, taste perversion, abdominal pain, flatulence, bloating
- Skin disorders: rash, dermatitis (including bullous eruptions), pruritus, alopecia
- Respiratory disorders: tracheal or tracheobronchial calcification
- General disorders: chills

7 DRUG INTERACTIONS

Drugs may interact with warfarin sodium through pharmacodynamic or pharmacokinetic mechanisms. Pharmacodynamic mechanisms for drug interactions with warfarin sodium are synergism (impaired hemostasis, reduced clotting factor synthesis), competitive antagonism (vitamin K), and alteration of the physiologic control loop for vitamin K metabolism (hereditary resistance). Pharmacokinetic mechanisms for drug interactions with warfarin sodium are mainly enzyme induction, enzyme inhibition, and reduced plasma protein binding. It is important to note that some drugs may interact by more than one mechanism.

More frequent INR monitoring should be performed when starting or stopping other drugs, including botanicals, or when changing dosages of other drugs, including drugs intended for short-term use (e.g., antibiotics, antifungals, corticosteroids) [see *Boxed Warning*]. Consult the labeling of all concurrently used drugs to obtain further information about interactions with warfarin sodium or adverse reactions pertaining to bleeding.

7.1 CYP450 Interactions

CYP450 isozymes involved in the metabolism of warfarin include CYP2C9, 2C19, 2C8, 2C18, 1A2, and 3A4. The more potent warfarin *S*-enantiomer is metabolized by CYP2C9 while the *R*-enantiomer is metabolized by CYP1A2 and 3A4.

- Inhibitors of CYP2C9, 1A2, and/or 3A4 have the potential to increase the effect (increase INR) of warfarin by increasing the exposure of warfarin.
- Inducers of CYP2C9, 1A2, and/or 3A4 have the potential to decrease the effect (decrease INR) of warfarin by decreasing the exposure of warfarin.

Examples of inhibitors and inducers of CYP2C9, 1A2, and 3A4 are below in Table 2; however, this list should not be considered all-inclusive. Consult the labeling of all concurrently used drugs to obtain further information about CYP450 interaction potential. The CYP450 inhibition and induction potential

should be considered when starting, stopping, or changing dose of concomitant mediations. Closely monitor INR if a concomitant drug is a CYP2C9, 1A2, and/or 3A4 inhibitor or inducer.

Enzyme	Inhibitors	Inducers					
CYP2C9	amiodarone, capecitabine, cotrimoxazole, etravirine, fluconazole, fluvastatin, fluvoxamine, metronidazole, miconazole, oxandrolone, sulfinpyrazone, tigecycline, voriconazole, zafirlukast	aprepitant, bosentan, carbamazepine, phenobarbital, rifampin					
CYP1A2	acyclovir, allopurinol, caffeine, cimetidine, ciprofloxacin, disulfiram, enoxacin, famotidine, fluvoxamine, methoxsalen, mexiletine, norfloxacin, oral contraceptives, phenylpropanolamine, propafenone, propranolol, terbinafine, thiabendazole, ticlopidine, verapamil, zileuton	montelukast, moricizine, omeprazole, phenobarbital, phenytoin, cigarette smoking					
CYP3A4	alprazolam, amiodarone, amlodipine, amprenavir, aprepitant, atorvastatin, atazanavir, bicalutamide, cilostazol, cimetidine, ciprofloxacin, clarithromycin, conivaptan, cyclosporine, darunavir/ritonavir, diltiazem, erythromycin, fluconazole, fluoxetine, fluvoxamine, fosamprenavir, imatinib, indinavir, isoniazid, itraconazole, ketoconazole, lopinavir/ritonavir, nefazodone, nelfinavir, nilotinib, oral contraceptives, posaconazole, ranitidine, ranolazine, ritonavir, saquinavir, telithromycin, tipranavir, voriconazole, zileuton	armodafinil, amprenavir, aprepitant, bosentan, carbamazepine, efavirenz, etravirine, modafinil, nafcillin, phenytoin, pioglitazone, prednisone, rifampin, rufinamide					

Table 2: Examples of CYP450 Interactions with Warfarin

7.2 Drugs that Increase Bleeding Risk

Examples of drugs known to increase the risk of bleeding are presented in Table 3. Because bleeding risk is increased when these drugs are used concomitantly with warfarin, closely monitor patients receiving any such drug with warfarin.

Drug Class	Specific Drugs
Anticoagulants	argatroban, dabigatran, bivalirudin, desirudin, heparin, lepirudin
Antiplatelet Agents	aspirin, cilostazol, clopidogrel, dipyridamole, prasugrel, ticlopidine
Nonsteroidal Anti- Inflammatory Agents	celecoxib, diclofenac, diflunisal, fenoprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, mefenamic acid, naproxen, oxaprozin, piroxicam, sulindac
Serotonin Reuptake Inhibitors	citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, paroxetine, sertraline, venlafaxine, vilazodone

Table 3: Drugs that Can Increase the Risk of Bleedin
--

7.3 Antibiotics and Antifungals

There have been reports of changes in INR in patients taking warfarin and antibiotics or antifungals, but clinical pharmacokinetic studies have not shown consistent effects of these agents on plasma concentrations of warfarin.

Closely monitor INR when starting or stopping any antibiotic or antifungal in patients taking warfarin.

7.4 Botanical (Herbal) Products and Foods

Exercise caution when botanical (herbal) products are taken concomitantly with warfarin sodium. Few adequate, well-controlled studies evaluating the potential for metabolic and/or pharmacologic interactions between botanicals and warfarin sodium exist. Due to a lack of manufacturing standardization with botanical medicinal preparations, the amount of active ingredients may vary. This could further confound the ability to assess potential interactions and effects on anticoagulation.

Some botanicals may cause bleeding events when taken alone (e.g., garlic and Ginkgo biloba) and may have anticoagulant, antiplatelet, and/or fibrinolytic properties. These effects would be expected to be additive to the anticoagulant effects of warfarin sodium. Conversely, some botanicals may decrease the effects of warfarin sodium (e.g., co-enzyme Q_{10} , St. John's wort ginseng). Some botanicals and foods can interact with warfarin sodium through CYP450 interactions (e.g., echinacea, grapefruit juice, ginkgo, goldenseal, St. John's wort).

Monitor the patient's response with additional INR determinations when initiating or discontinuing any botanicals.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Pregnancy Category D for women with mechanical heart valves [see *Warnings and Precautions* (5.5)] and **Pregnancy Category X** for other pregnant populations [see *Contraindications* (4)].

Warfarin Sodium Tablets, USP are contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism, and for whom the benefits of warfarin sodium may outweigh the risks. Warfarin sodium can cause fetal harm when administered to a pregnant woman. Warfarin sodium exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy), fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. The reproductive and developmental effects of warfarin sodium have not been evaluated in animals. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.

In humans, warfarin crosses the placenta, and concentrations in fetal plasma approach the maternal values. Exposure to warfarin during the first trimester of pregnancy caused a pattern of congenital malformations in about 5% of exposed offspring. Warfarin embryopathy is characterized by nasal hypoplasia with or without stippled epiphyses (chondrodysplasia punctata) and growth retardation (including low birth weight). Central nervous system and eye abnormalities have also been reported, including dorsal midline dysplasia characterized by agenesis of the corpus callosum, Dandy-Walker malformation, midline cerebellar atrophy, and ventral midline dysplasia characterized by optic atrophy. Mental retardation, blindness, schizencephaly, microcephaly, hydrocephalus, and other adverse pregnancy outcomes have been reported following warfarin exposure during the second and third trimesters of pregnancy [see *Contraindications (4)* and *Warnings and Precautions (5.6)*].

8.3 Nursing Mothers

Based on published data in 15 nursing mothers, warfarin was not detected in human milk. Among the 15 full-term newborns, 6 nursing infants had documented prothrombin times within the expected range. Prothrombin times were not obtained for the other 9 nursing infants. Monitor breast-feeding infants for

bruising or bleeding. Effects in premature infants have not been evaluated. Caution should be exercised when warfarin sodium is administered to a nursing woman.

8.4 Pediatric Use

Adequate and well-controlled studies with warfarin sodium have not been conducted in any pediatric population, and the optimum dosing, safety, and efficacy in pediatric patients is unknown. Pediatric use of warfarin sodium is based on adult data and recommendations, and available limited pediatric data from observational studies and patient registries. Pediatric patients administered warfarin sodium should avoid any activity or sport that may result in traumatic injury.

The developing hemostatic system in infants and children results in a changing physiology of thrombosis and response to anticoagulants. Dosing of warfarin in the pediatric population varies by patient age, with infants generally having the highest, and adolescents having the lowest milligram per kilogram dose requirements to maintain target INRs. Because of changing warfarin requirements due to age, concomitant medications, diet, and existing medical condition, target INR ranges may be difficult to achieve and maintain in pediatric patients, and more frequent INR determinations are recommended. Bleeding rates varied by patient population and clinical care center in pediatric observational studies and patient registries.

Infants and children receiving vitamin K-supplemented nutrition, including infant formulas, may be resistant to warfarin therapy, while human milk-fed infants may be sensitive to warfarin therapy.

8.5 Geriatric Use

Of the total number of patients receiving warfarin sodium in controlled clinical trials for which data were available for analysis, 1885 patients (24.4%) were 65 years and older, while 185 patients (2.4%) were 75 years and older. No overall differences in effectiveness or safety were observed between these patients and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

Patients 60 years or older appear to exhibit greater than expected INR response to the anticoagulant effects of warfarin [see *Clinical Pharmacology (12.3)*]. Warfarin sodium is contraindicated in any unsupervised patient with senility. Observe caution with administration of warfarin sodium to elderly patients in any situation or with any physical condition where added risk of hemorrhage is present. Consider lower initiation and maintenance doses of warfarin sodium in elderly patients [see *Dosage and Administration (2.2, 2.3)*].

8.6 Renal Impairment

Renal clearance is considered to be a minor determinant of anticoagulant response to warfarin. No dosage adjustment is necessary for patients with renal impairment.

8.7 Hepatic Impairment

Hepatic impairment can potentiate the response to warfarin through impaired synthesis of clotting factors and decreased metabolism of warfarin. Use caution when using warfarin sodium in these patients.

8.8 Females of Reproductive Potential

Warfarin sodium exposure during pregnancy can cause spontaneous abortion, birth defects, or fetal death. Females of reproductive potential who are candidates for warfarin sodium therapy should be counseled regarding the benefits of therapy and potential reproductive risks. Discuss pregnancy planning with females of reproductive potential who are on warfarin sodium therapy. If the patient becomes pregnant while taking warfarin sodium, she should be apprised of the potential risks to the fetus.

10.1 Signs and Symptoms

Bleeding (e.g., appearance of blood in stools or urine, hematuria, excessive menstrual bleeding, melena, petechiae, excessive bruising or persistent oozing from superficial injuries, unexplained fall in hemoglobin) is a manifestation of excessive anticoagulation.

10.2 Treatment


The treatment of excessive anticoagulation is based on the level of the INR, the presence or absence of bleeding, and clinical circumstances. Reversal of warfarin sodium anticoagulation may be obtained by discontinuing warfarin sodium therapy and, if necessary, by administration of oral or parenteral vitamin K_1 .

The use of vitamin K_1 reduces response to subsequent warfarin sodium therapy and patients may return to a pretreatment thrombotic status following the rapid reversal of a prolonged INR. Resumption of warfarin sodium administration reverses the effect of vitamin K, and a therapeutic INR can again be obtained by careful dosage adjustment. If rapid re-anticoagulation is indicated, heparin may be preferable for initial therapy.

Prothrombin complex concentrate (PCC), fresh frozen plasma, or activated Factor VII treatment may be considered if the requirement to reverse the effects of warfarin sodium is urgent. A risk of hepatitis and other viral diseases is associated with the use of blood products; PCC and activated Factor VII are also associated with an increased risk of thrombosis. Therefore, these preparations should be used only in exceptional or life-threatening bleeding episodes secondary to warfarin sodium overdosage.

11 DESCRIPTION

Warfarin sodium is an anticoagulant that acts by inhibiting vitamin K-dependent coagulation factors. Chemically, it is 3-(α -acetonylbenzyl)-4-hydroxycoumarin and is a racemic mixture of the *R*- and *S*-enantiomers. Crystalline warfarin sodium is an isopropanol clathrate. Its empirical formula is C₁₉H₁₅NaO₄, and its structural formula is represented by the following:



Crystalline warfarin sodium occurs as a white, odorless, crystalline powder that is discolored by light. It is very soluble in water, freely soluble in alcohol, and very slightly soluble in chloroform and ether.

Warfarin Sodium Tablets, USP for oral use also contain:

All strengths: Anhydrous lactose, corn starch, and magnesium stearate

1 mg:	D&C Red No. 6 Barium Lake.
2 mg:	FD&C Blue No. 2 Aluminum Lake, FD&C Red No. 40 Aluminum Lake.
2.5 mg:	D&C Yellow No. 10 Aluminum Lake, FD&C Blue No. 2 Aluminum Lake.
3 mg:	D&C Yellow No. 10 Aluminum Lake, FD&C Blue No. 2 Aluminum Lake, FD&C Red No. 40 Aluminum Lake.
4 mg:	FD&C Blue No. 1 Aluminum Lake.
5 mg:	D&C Red No. 6 Barium Lake, D&C Yellow No. 10 Aluminum Lake.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Warfarin acts by inhibiting the synthesis of vitamin K-dependent clotting factors, which include Factors II, VII, IX, and X, and the anticoagulant proteins C and S. Vitamin K is an essential cofactor for the post ribosomal synthesis of the vitamin K-dependent clotting factors. Vitamin K promotes the biosynthesis of γ -carboxyglutamic acid residues in the proteins that are essential for biological activity. Warfarin is thought to interfere with clotting factor synthesis by inhibition of the C1 subunit of vitamin K epoxide reductase (VKORC1) enzyme complex, thereby reducing the regeneration of vitamin K₁ epoxide [see *Clinical Pharmacology (12.5)*].

12.2 Pharmacodynamics

An anticoagulation effect generally occurs within 24 hours after warfarin administration. However, peak anticoagulant effect may be delayed 72 to 96 hours. The duration of action of a single dose of racemic warfarin is 2 to 5 days. The effects of warfarin sodium may become more pronounced as effects of daily maintenance doses overlap. This is consistent with the half-lives of the affected vitamin K-dependent clotting factors and anticoagulation proteins: Factor II - 60 hours, VII - 4 to 6 hours, IX - 24 hours, X - 48 to 72 hours, and proteins C and S are approximately 8 hours and 30 hours, respectively.

12.3 Pharmacokinetics

Warfarin sodium is a racemic mixture of the *R*- and *S*-enantiomers of warfarin. The *S*-enantiomer exhibits 2 to 5 times more anticoagulant activity than the *R*-enantiomer in humans, but generally has a more rapid clearance.

Absorption

Warfarin is essentially completely absorbed after oral administration, with peak concentration generally attained within the first 4 hours.

Distribution

Warfarin distributes into a relatively small apparent volume of distribution of about 0.14 L/kg. A distribution phase lasting 6 to 12 hours is distinguishable after rapid intravenous or oral administration of an aqueous solution. Approximately 99% of the drug is bound to plasma proteins.

Metabolis m

The elimination of warfarin is almost entirely by metabolism. Warfarin is stereoselectively metabolized by hepatic cytochrome P-450 (CYP450) microsomal enzymes to inactive hydroxylated metabolites (predominant route) and by reductases to reduced metabolites (warfarin alcohols) with minimal anticoagulant activity. Identified metabolites of warfarin include dehydrowarfarin, two diastereoisomer alcohols, and 4' -, 6-, 7-, 8-, and 10-hydroxywarfarin. The CYP450 isozymes involved in the metabolism of warfarin include CYP2C9, 2C19, 2C8, 2C18, 1A2, and 3A4. CYP2C9, a polymorphic enzyme, is likely to be the principal form of human liver CYP450 that modulates the *in vivo* anticoagulant activity of warfarin. Patients with one or more variant CYP2C9 alleles have decreased S-warfarin clearance [see *Clinical Pharmacology (12.5)*].

Excretion

The terminal half-life of warfarin after a single dose is approximately 1 week; however, the effective half-life ranges from 20 to 60 hours, with a mean of about 40 hours. The clearance of R-warfarin is

generally half that of S-warfarin, thus as the volumes of distribution are similar, the half-life of R-warfarin is longer than that of S-warfarin. The half-life of R-warfarin ranges from 37 to 89 hours, while that of S-warfarin ranges from 21 to 43 hours. Studies with radiolabeled drug have demonstrated that up to 92% of the orally administered dose is recovered in urine. Very little warfarin is excreted unchanged in urine. Urinary excretion is in the form of metabolites.

Geriatric Patients

Patients 60 years or older appear to exhibit greater than expected INR response to the anticoagulant effects of warfarin. The cause of the increased sensitivity to the anticoagulant effects of warfarin in this age group is unknown but may be due to a combination of pharmacokinetic and pharmacodynamic factors. Limited information suggests there is no difference in the clearance of S-warfarin; however, there may be a slight decrease in the clearance of R-warfarin in the elderly as compared to the young. Therefore, as patient age increases, a lower dose of warfarin is usually required to produce a therapeutic level of anticoagulation [see *Dosage and Administration (2.3, 2.4)*].

Asian Patients

Asian patients may require lower initiation and maintenance doses of warfarin. A non-controlled study of 151 Chinese outpatients stabilized on warfarin for various indications reported a mean daily warfarin requirement of 3.3 ± 1.4 mg to achieve an INR of 2 to 2.5. Patient age was the most important determinant of warfarin requirement in these patients, with a progressively lower warfarin requirement with increasing age.

12.5 Pharmacogenomics

CYP2C9 and VKORC1 Polymorphisms

The *S*-enantiomer of warfarin is mainly metabolized to 7-hydroxywarfarin by CYP2C9, a polymorphic enzyme. The variant alleles, CYP2C9*2 and CYP2C9*3, result in decreased *in vitro* CYP2C9 enzymatic 7-hydroxylation of S-warfarin. The frequencies of these alleles in Caucasians are approximately 11% and 7% for CYP2C9*2 and CYP2C9*3, respectively. Other CYP2C9 alleles associated with reduced enzymatic activity occur at lower frequencies, including *5, *6, and *11 alleles in populations of African ancestry and *5, *9, and *11 alleles in Caucasians.

Warfarin reduces the regeneration of vitamin K from vitamin K epoxide in the vitamin K cycle through inhibition of VKOR, a multiprotein enzyme complex. Certain single nucleotide polymorphisms in the VKORC1 gene (e.g., –1639G>A) have been associated with variable warfarin dose requirements. VKORC1 and CYP2C9 gene variants generally explain the largest proportion of known variability in warfarin dose requirements.

CYP2C9 and VKORC1 genotype information, when available, can assist in selection of the initial dose of warfarin [see *Dosage and Administration (2.3)*].

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenicity, mutagenicity, or fertility studies have not been performed with warfarin.

14 CLINICAL STUDIES

14.1 Atrial Fibrillation

In five prospective, randomized, controlled clinical trials involving 3711 patients with nonrheumatic AF, warfarin significantly reduced the risk of systemic thromboembolism including stroke (see Table 4). The risk reduction ranged from 60% to 86% in all except one trial (CAFA: 45%), which was stopped early due to published positive results from two of these trials. The incidence of major bleeding in

these trials ranged from 0.6% to 2.7% (see Table 4).

	Ν			Thromboembolis		nbolis m	n % Major Bleeding	
Study	Warfarin- Treated Patients	Control Patients	PT Ratio	INR	% Risk Reduction	<i>p</i> -value	Warfarin- Treated Patients	Control Patients
AFASAK	335	336	1.5-2.0	2.8-4.2	60	0.027	0.6	0.0
SPAF	210	211	1.3-1.8	2.0-4.5	67	0.01	1.9	1.9
BAATAF	212	208	1.2-1.5	1.5-2.7	86	< 0.05	0.9	0.5
CAFA	187	191	1.3-1.6	2.0-3.0	45	0.25	2.7	0.5
SPINAF	260	265	1.2-1.5	1.4-2.8	79	0.001	2.3	1.5

 Table 4: Clinical Studies of Warfarin in Non-Rheumatic AF Patients*

* All study results of warfarin vs. control are based on intention-to-treat analysis and include ischemic stroke and systemic thromboembolism, excluding hemorrhagic stroke and transient ischemic attacks.

Trials in patients with both AF and mitral stenosis suggest a benefit from anticoagulation with warfarin sodium [see *Dosage and Administration (2.2)*].

14.2 Mechanical and Bioprosthetic Heart Valves

In a prospective, randomized, open-label, positive-controlled study in 254 patients with mechanical prosthetic heart valves, the thromboembolic-free interval was found to be significantly greater in patients treated with warfarin alone compared with dipyridamole/aspirin-treated patients (p<0.005) and pentoxifylline/aspirin-treated patients (p<0.05). The results of this study are presented in Table 5.

Table 5: Prospective, Randomized, Open-Label, Positive-Controlled ClinicalStudy of Warfarin in Patients with Mechanical Prosthetic Heart Valves

	Patients Treated With			
Event	Warfarin	Dipyridamole/ Aspirin	Pentoxifylline/ Aspirin	
Thromboembolism	2.2/100 py	8.6/100 py	7.9/100 py	
Major Bleeding	2.5/100 py	0.0/100 py	0.9/100 py	

py= patient years

In a prospective, open-label, clinical study comparing moderate (INR 2.65) vs. high intensity (INR 9.0) warfarin therapies in 258 patients with mechanical prosthetic heart valves, thromboembolism occurred with similar frequency in the two groups (4.0 and 3.7 events per 100 patient years, respectively). Major bleeding was more common in the high intensity group. The results of this study are presented in Table 6.

Table 6: Prospective, Open-Label Clinical Study of Warfarin in Patients withMechanical Prosthetic Heart Valves

Event	Moderate Warfarin Therapy INR 2.65	High Intensity Warfarin Therapy INR 9.0
Thromboembolism	4.0/100 py	3.7/100 py
Major Bleeding	0.95/100 py	2.1/100 py

py= patient years

In a randomized trial in 210 patients comparing two intensities of warfarin therapy (INR 2.0-2.25 vs. INR

2.5-4.0) for a three-month period following tissue heart valve replacement, thromboembolism occurred with similar frequency in the two groups (major embolic events 2.0% vs. 1.9%, respectively, and minor embolic events 10.8% vs. 10.2%, respectively). Major hemorrhages occurred in 4.6% of patients in the higher intensity INR group compared to zero in the lower intensity INR group.

14.3 Myocardial Infarction

WARIS (The Warfarin Re-Infarction Study) was a double-blind, randomized study of 1214 patients 2 to 4 weeks post-infarction treated with warfarin to a target INR of 2.8 to 4.8. The primary endpoint was a composite of total mortality and recurrent infarction. A secondary endpoint of cerebrovascular events was assessed. Mean follow-up of the patients was 37 months. The results for each endpoint separately, including an analysis of vascular death, are provided in Table 7:

Event	Warfarin (N=607)	Placebo (N=607)	RR (95% CI)	% Risk Reduction (p-value)
Total Patient				
Years of Follow-				
up	2018	1944		
Total Mortality	94 (4.7/100 py)	123 (6.3/100 py)	0.76 (0.60, 0.97)	24 (p=0.030)
Vascular Death	82 (4.1/100 py)	105 (5.4/100 py)	0.78 (0.60, 1.02)	22 (p=0.068)
Recurrent MI	82 (4.1/100 py)	124 (6.4/100 py)	0.66 (0.51, 0.85)	34 (p=0.001)
Cerebrovascular Event	20 (1.0/100 py)	44 (2.3/100 py)	0.46 (0.28, 0.75)	54 (p=0.002)

Table 7: WARIS – Endpoint Analysis of Separate Events

RR=Relative risk; Risk reduction=(1-RR); CI=Confidence interval; MI=Myocardial infarction; py=patient years

WARIS II (The Warfarin, Aspirin, Re-Infarction Study) was an open-label, randomized study of 3630 patients hospitalized for acute myocardial infarction treated with warfarin to a target INR 2.8 to 4.2, aspirin 160 mg per day, or warfarin to a target INR 2.0 to 2.5 plus aspirin 75 mg per day prior to hospital discharge. The primary endpoint was a composite of death, nonfatal reinfarction, or thromboembolic stroke. The mean duration of observation was approximately 4 years. The results for WARIS II are provided in the Table 8.

Event	Aspirin (N=1206)	Warfarin (N=1216)	Aspirin plus Warfarin (N=1208)	Rate Ratio (95% CI)	<i>p</i> -value
		No. of Events	6		
Major Bleeding [*]	8	33	28	3.35 [†] (ND) 4.00 [‡] (ND)	ND ND
Minor Bleeding [§]	39	103	133	3.21 [†] (ND) 2.55 [‡] (ND)	ND ND
Composite Endpoints¶	241	203	181	$0.81(0.69{-}0.95)^{\dagger}\ 0.71(0.60{-}0.83)^{\ddagger}$	0.03 0.001
Reinfarction	117	90	69	$0.56 (0.41-0.78)^{\dagger} \ 0.74 (0.55-0.98)^{\ddagger}$	<0.001 0.03
Thromboembolic Stroke	32	17	17	0.52 (0.28-0.98) [†] 0.52 (0.28-0.97) [‡]	0.03 0.03

Death	92	96	95	0.82
CI=confidence interval				

ND=not determined

- * Major bleeding episodes were defined as nonfatal cerebral hemorrhage or bleeding necessitating surgical intervention or blood transfusion.
- [†] The rate ratio is for aspirin plus warfarin as compared with aspirin.
- [‡] The rate ratio is for warfarin as compared with aspirin.
- § Minor bleeding episodes were defined as non-cerebral hemorrhage not necessitating surgical intervention or blood transfusion.
- ¶ Includes death, nonfatal reinfarction, and thromboembolic cerebral stroke.

There were approximately four times as many major bleeding episodes in the two groups receiving warfarin than in the group receiving aspirin alone. Major bleeding episodes were not more frequent among patients receiving aspirin plus warfarin than among those receiving warfarin alone, but the incidence of minor bleeding episodes was higher in the combined therapy group.

15 REFERENCES

- Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 8th Ed. *Chest.* 2008;133:160S-198S.
- Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 8th Ed. *Chest.* 2008;133:454S-545S.
- Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 8th Ed. *Chest.* 2008;133:546S-592S.
- Becker RC, Meade TW, Berger PB, et al. The primary and secondary prevention of coronary artery disease. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 8th Ed. *Chest.* 2008;133:776S-814S.
- Salem DN, O'Gara PT, Madias C, Pauker SG. Valvular and structural heart disease. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 8th Ed. *Chest.* 2008;133:593S-629S.
- Monagle P, Chalmers E, Chan A, et al. Antithrombotic therapy in neonates and children. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 8th Ed. *Chest*. 2008;133:887S-968S.

16 HOW SUPPLIED/STORAGE AND HANDLING

Tablets

Warfarin Sodium Tablets, USP are single scored, flat beveled capsule shaped tablets, engraved numerically with 1, 2, 2½, 3, 4, 5, 6, 7½, or 10 on one side and engraved with "WARFARIN" on top of "TARO" on the other side. They are packaged with potencies and colors as follows:

	Color	Engraving	Bottles of 30
1 mg	Pink	1	NDC 51138-054-30
2 mg	Lavender	2	NDC 51138-055-30
2.5 mg	Green	2 1/2	NDC 51138-056-30
3 mg	Tan	3	NDC 51138-057-30
4 mg	Blue	4	NDC 51138-058-30
5 mg	Peach	5	NDC 51138-059-30
0			

6 mg	Teal	6	NDC 51138-060-30
7.5 mg	Yellow	7 1/2	NDC 51138-061-30
10 mg	White (dye free)	10	NDC 51138-062-30

Protect from light and moisture. **Store at 20°-25°C (68°-77°F)** [see USP Controlled Room Temperature].

Dispense in a tight, light-resistant container as defined in the USP.

Store the unit-dose blister packages in the carton until contents have been used.

17 PATIENT COUNSELING INFORMATION

See FDA-approved patient labeling (Medication Guide).

Advise patients to:

- Tell their physician if they fall often as this may increase their risk for complications.
- Strictly adhere to the prescribed dosage schedule. Do not take or discontinue any other drug, including salicylates (e.g., aspirin and topical analgesics), other over-the-counter drugs, and botanical (herbal) products except on advice of your physician.
- Notify their physician immediately if any unusual bleeding or symptoms occur. Signs and symptoms of bleeding include: pain, swelling or discomfort, prolonged bleeding from cuts, increased menstrual flow or vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or dark brown urine, red or tar black stools, headache, dizziness, or weakness.
- Contact their doctor
 - immediately if they think they are pregnant
 - to discuss pregnancy planning
 - if they are considering breast-feeding
- Avoid any activity or sport that may result in traumatic injury.
- Obtain prothrombin time tests and make regular visits to their physician or clinic to monitor therapy.
- Carry identification stating that they are taking warfarin sodium.
- If the prescribed dose of warfarin sodium is missed, take the dose as soon as possible on the same day but do not take a double dose of warfarin sodium the next day to make up for missed doses.
- Eat a normal, balanced diet to maintain a consistent intake of vitamin K. Avoid drastic changes in dietary habits, such as eating large amounts of leafy, green vegetables.
- Contact their physician to report any serious illness, such as severe diarrhea, infection, or fever.
- Be aware that if therapy with warfarin sodium is discontinued, the anticoagulant effects of warfarin sodium may persist for about 2 to 5 days.

Mfd. by: Taro Pharmaceutical Industries Ltd., Haifa Bay, Israel 26110

Dist. by: Taro Pharmaceuticals U.S.A., Inc., Hawthorne, NY 10532

Revised: November 2011 90145-1111-13

Repackaged By:

Med-Health Pharma, LLC North Las Vegas, NV 89032

SP-60016 Rev01

MEDICATION GUIDE

Warfarin Sodium Tablets, USP

Read this Medication Guide before you start taking warfarin sodium and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking to your healthcare provider about your medical condition or treatment. You and your healthcare provider should talk about warfarin sodium when you start taking it and at regular checkups.

What is the most important information I should know about warfarin sodium?

Warfarin sodium can cause bleeding which can be serious and sometimes lead to death. This is because warfarin sodium is a blood thinner medicine that lowers the chance of blood clots forming in your body.

- You may have a higher risk of bleeding if you take warfarin sodium and:
 - are 65 years of age or older
 - have a history of stomach or intestinal bleeding
 - have high blood pressure (hypertension)
 - have a history of stroke, or "mini-stroke" (transient ischemic attack or TIA)
 - have serious heart disease
 - have a low blood count or cancer
 - have had trauma, such as an accident or surgery
 - have kidney problems
 - take other medicines that increase your risk of bleeding, including:
 - a medicine that contains heparin
 - other medicines to prevent or treat blood clots
 - nonsteroidal anti-inflammatory drugs (NSAIDs)
 - take warfarin sodium for a long time. Warfarin sodium is the active ingredient in Warfarin Sodium Tablets, USP.

Tell your healthcare provider if you take any of these medicines. Ask your healthcare provider if you are not sure if your medicine is one listed above.

Many other medicines can interact with warfarin sodium and affect the dose you need or increase warfarin sodium side effects. Do not change or stop any of your medicines or start any new medicines before you talk to your healthcare provider.

Do not take other medicines that contain warfarin sodium while taking Warfarin Sodium Tablets, USP.

- **Get your regular blood test to check for your response to warfarin sodium.** This blood test is called an INR test. The INR test checks to see how fast your blood clots. Your healthcare provider will decide what INR numbers are best for you. Your dose of warfarin sodium will be adjusted to keep your INR in a target range for you.
- Call your healthcare provider right away if you get any of the following signs or symptoms of bleeding problems:
 - pain, swelling, or discomfort
 - headaches, dizziness, or weakness
 - unusual bruising (bruises that develop without known cause or grow in size)
 - nosebleeds
 - bleeding gums
 - bleeding from cuts takes a long time to stop
 - menstrual bleeding or vaginal bleeding that is heavier than normal
 - pink or brown urine
 - red or black stools
 - coughing up blood
 - vomiting blood or material that looks like coffee grounds

- Some foods and beverages can interact with warfarin sodium and affect your treatment and dose.
 - Eat a normal, balanced diet. Talk to your healthcare provider before you make any diet changes. Do not eat large amounts of leafy, green vegetables. Leafy, green vegetables contain vitamin K. Certain vegetable oils also contain large amounts of vitamin K. Too much vitamin K can lower the effect of warfarin sodium.
- Always tell all of your healthcare providers that you take warfarin sodium.
- Wear or carry information that you take warfarin sodium.

See "What are the possible side effects of warfarin sodium?" for more information about side effects.

What is warfarin sodium?

Warfarin sodium is prescription medicine used to treat blood clots and to lower the chance of blood clots forming in your body. Blood clots can cause a stroke, heart attack, or other serious conditions if they form in the legs or lungs.

It is not known if warfarin sodium is safe and effective in children.

Who should not take warfarin sodium?

Do not take warfarin sodium if:

- **your chance of having bleeding problems is higher than the possible benefit of treatment.** Your healthcare provider will decide if warfarin sodium is right for you. Talk to your healthcare provider about all of your health conditions.
- **you are pregnant unless you have a mechanical heart valve.** Warfarin sodium may cause birth defects, miscarriage, or death of your unborn baby.
- you are allergic to warfarin or any of the other ingredients in Warfarin Sodium Tablets, USP. See the end of this leaflet for a complete list of ingredients in Warfarin Sodium Tablets, USP.

What should I tell my healthcare provider before taking warfarin sodium?

Before you take warfarin sodium, tell your healthcare provider if you:

- have bleeding problems
- fall often
- have liver or kidney problems
- have high blood pressure
- have a heart problem called congestive heart failure
- have diabetes
- plan to have any surgery or a dental procedure
- have any other medical conditions
- are pregnant or plan to become pregnant. See "Who should not take warfarin sodium?"
- are breast-feeding. You and your healthcare provider should decide if you will take warfarin sodium and breast-feed.

Tell all of your healthcare providers and dentists that you are taking warfarin sodium. They should talk to the healthcare provider who prescribed warfarin sodium for you before you have **any** surgery or dental procedure. Your warfarin sodium may need to be stopped for a short time or your may need your dose adjusted.

Tell your healthcare provider about all the medicines you take, including prescription and nonprescription medicines, vitamins, and herbal supplements. Some of your other medicines may affect the way warfarin sodium works. Certain medicines may increase your risk of bleeding. See "What is the most important information I should know about warfarin sodium?"

Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist

when you get a new medicine.

How should I take warfarin sodium?

- **Take warfarin sodium exactly as prescribed.** Your healthcare provider will adjust your dose from time to time depending on your response to warfarin sodium.
- You must have regular blood tests and visits with your healthcare provider to monitor your condition.
- **If you miss a dose of warfarin sodium, call your healthcare provider.** Take the dose as soon as possible on the same day. **Do not** take a double dose of warfarin sodium the next day to make up for a missed dose.
- Call your healthcare provider right away if you:
 - take too much warfarin sodium
 - are sick with diarrhea, an infection, or have a fever
 - fall or injure yourself, especially if you hit your head. Your healthcare provider may need to check you

What should I avoid while taking warfarin sodium?

• Do not do any activity or sport that may cause a serious injury.

What are the possible side effects of warfarin sodium?

Warfarin sodium may cause serious side effects including:

- See "What is the most important information I should know about warfarin sodium?"
 - **Death of skin tissue (skin necrosis or gangrene).** This can happen soon after starting warfarin sodium. It happens because blood clots form and block blood flow to an area of your body. Call your healthcare provider right away if you have pain, color, or temperature change to any area of your body. You may need medical care right away to prevent death or loss (amputation) of your affected body part.
 - "**Purple toes syndrome.**" Call your healthcare provider right away if you have pain in your toes and they look purple in color or dark in color.

Tell your healthcare provider if you have any side effect that bothers you or does not go away.

These are not all of the side effects of warfarin sodium. For more information, ask your healthcare provider or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store Warfarin Sodium Tablets, USP?

- Store warfarin sodium at 68°F to 77°F (20°C to 25°C).
- Keep warfarin sodium in a tightly closed container, and keep warfarin sodium out of the light.

Keep Warfarin Sodium Tablets, USP and all medicines out of the reach of children.

General information about warfarin sodium.

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use warfarin sodium for a condition for which it was not prescribed. Do not give warfarin sodium to other people, even if they have the same symptoms that you have. It may harm them.

This Medication Guide summarizes the most important information about warfarin sodium. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about warfarin sodium that is written for healthcare professionals.

What are the ingredients in Warfarin Sodium Tablets, USP?

Active ingredient: Warfarin Sodium

Inactive ingredients: Anhydrous lactose, corn starch, and magnesium stearate

1 mg:	D&C Red No. 6 Barium Lake
2 mg:	FD&C Blue No. 2 Aluminum Lake, FD&C Red No. 40 Aluminum Lake
2.5 mg:	D&C Yellow No. 10 Aluminum Lake, FD&C Blue No. 2 Aluminum Lake
3 mg:	D&C Yellow No. 10 Aluminum Lake, FD&C Blue No. 2 Aluminum Lake, FD&C Red No. 40 Aluminum Lake
4 mg:	FD&C Blue No. 1 Aluminum Lake
5 mg:	D&C Red No. 6 Barium Lake, D&C Yellow No. 10 Aluminum Lake
6 mg:	D&C Yellow No. 10 Aluminum Lake, FD&C Blue No. 2 Aluminum Lake
7.5 mg:	D&C Yellow No. 10 Aluminum Lake

This Medication Guide has been approved by the U.S. Food and Drug Administration.

Mfd. by: Taro Pharmaceutical Industries Ltd., Haifa Bay, Israel 26110

Dist. by: Taro Pharmaceuticals U.S.A., Inc., Hawthorne, NY 10532

Revised: October 2011

**The brands listed are registered trademarks of their respective owners and are not trademarks of Taro Pharmaceuticals U.S.A., Inc. or its affiliates.

Revised: November, 2011 90145-1111-13

Repackaged By:

Med-Health Pharma, LLC North Las Vegas, NV 89032

SP-60016 Rev01

PRINCIPAL DISPLAY PANEL - 1 mg Tablet Bottle Label



PRINCIPAL DISPLAY PANEL - 2 mg Tablet Bottle Label

Wartanin Sadium 2mg 51138-055-30 Lut EXp	Store at controlled Room Temperature 20°-25° C (68°-77° F)	NDC 51138-055-30	ГН		
Warfarin Sodium 2mg 61130 065 30 Lot Exp	See package Insert for full proscribing	Warfarin Sodium Tablets, USP 2mg	C rystalline x Only ^s	e i	
Warfarin Sodium 2mg 51130-055-30 Lot Exp	information "Caution: Federal Law Prohibits Dispensing Without a Prescription	HIGHLY POTENT ANTICOAGULANT WARNING: Serious bleeding results from Do not use or dispense before reading di warnings in accompanying package inse	irections and		
Wanfarin Godium 2mg 51138-055-30 Lot Exp	Manufactured by: Taro Pharmaceutical Ind. Haifa Bay, Israel 26110	1 077 005 5551	010101	Lot Exp	

PRINCIPAL DISPLAY PANEL - 2.5 mg Tablet Bottle Label



PRINCIPAL DISPLAY PANEL - 3 mg Tablet Bottle Label

Warfarın Sorkum Jiniq 51138-057-30 Lor Exp	Store at controlled Room Temperature 20°-25° C (58°-77° F)	NDC 51138-057-30	
Varfarin Gorlium Jung 51138-057-30 Lot Exp	See package insert for full prescribing	Warfarin Sodium Tablets, USP Crystalline 3mg 30 Tablets Rx Only *	
Varlarin Sodium 3mg X1138.057.30 .ot Exp	Information "Caution: Federal Law Prohibits Dispensing Without a Prescription	HIGHLY POTENT ANTICOAGULANT WARNING, Serious bleeding results from overdosage. Do not use or dispense before reading directions and warnings in accompanying package insert.	
Varfarin Sodium 3mg https://www.sodium Lot Exu	Manufactured by: Taro Pharmaceutical Ind. Haifa Bay, Israel 26110	Repuckaged by: Med-Health Pharma, LLC Sub North Las Vegas, NV 89032 1-877-896-6654 etezet	

PRINCIPAL DISPLAY PANEL - 4 mg Tablet Bottle Label



PRINCIPAL DISPLAY PANEL - 5 mg Tablet Bottle Label



PRINCIPAL DISPLAY PANEL - 6 mg Tablet Bottle Label

Wartaiin Sodium 6mg 51138-060-30 Lot Exp	Store at controlled Room Temperature 20°-25° C (68°-77° F) (See USP)	NDC 51138-060-30	
Warfanin Sochum fiong 51138 060-30 Lot Exp	See package insert for full prescribing	Warfarin Sodium Tablets, USP Crystalline 6mg 30 Tablets Rx Only *	
Warfacin Sorlium Grog 51138-060-30 Lot Exp	information *Caution: Federal Law Prohibits Dispensing Without a Prescription	HIGHLY POTENT ANTICOAGULANT WARNING: Serious bleeding results from overdosage Do not use or dispense before reading directions and warnings in accompanying package insert.	
Warfatin Sodium fing 51138-060-30 Lot Exp	Manufactured by: Taro Pharmaceutical Ind. Haifa Bay, Israel 26110	Repackaged by: Med-Health Pharma, LLC North Las Vegas, NV 89032 1-877-896-6654 010201	E C

PRINCIPAL DISPLAY PANEL - 7.5 mg Tablet Bottle Label

Wartarin Sodium 7.5mg 51138-061-30 Lot Exp	Store at controlled Room Temperature 20°-25° C (68°-77° F) (See USP)	NDC 51138-061-30		
Warfarin Sodium 7.5mg 51138-061-30 Lot Exp	Dosage Use: See package insert for full prescribing	Warfarin Sodium Tablets, USP Crystalline 7.5mg 30 Tablets Rx Only ⁻		13806130
Werfatin Sodium 7.5mg 51138-061-30 Lot Exp	information 'Caution: Federal Law Prohibits Dispensing Without a Prescription	HIGHLY POTENT ANTICOAGULANT WARNING: Scrious bleeding results from overdosage. Do not use or disponse before reading directions and warnings in accompanying package insert.		01)00351
Warfarin Sodkun 7.5mg 51138-061-30 Lot Exp	Manufactured by: Taro Pharmaceutical Ind. Haila Bay, Israel 26110	Repackaged by: Med-Health Pharma, LLC North Las Vegas, NV 89032 1-877-896-6654 e19201	E Co	

PRINCIPAL DISPLAY PANEL - 10 mg Tablet Bottle Label

Warfarin Sorlium 10mg \$1138-062-30 Lot Exp	Store at controlled Room Temperature 20°-25° C (68°-77° F)		L.C.		
Warfarin Sodium 10mg 51138-062-30 Lot Exp	See package insert for full prescribing	NDC 51138-062-30 Warfarin Sodium Tablets, US 10mg 30 Tablets			
Vartanin Sochum 10mg 1138-062-30 of ×p	information *Caution: Federal Law Prohibits Disponsing Without a Prescription	HIGHLY POTENT ANTICOAGULANT WARNING: Serious bleeding results Do not use or dispense before readin warnings in accompanying package	ng directions and		
Vartarin Sodium 10mg 1138-062-38 .ot .ot	Manufactured by: Taro Pharmaceutical Ind. Harta Bay, Israel 26110	Repackaged by: Med-Health Pharma, LLC North Las Vegas, NV 8903 1-877-896-6654	2	ă <u>ة</u>	

WARFARIN SODIUM

warfarin sodium tablet

-					
Product Information					
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source) NDC:5	1138-054(ND	C:51672-4027)
Route of Administration	ORAL				
A. (* T. 1* . /A. (* 3.4.*					
Active Ingredient/Active Moi	ety				
Ing	redient Name]	Basis of	Strength	Strength
Warfarin Sodium (UNII: 6153CWM0C)	L) (Warfarin - UNII:5Q7ZVV76EI)	Wa	rfarin Sod	ium	1 mg
Inactive Ingredients					
	Ingredient Name			Stro	ength
anhydrous lactose (UNII: 3SY5LH9PM	К)				

magnesium st	tearate (UNI	I: 70097M6I	30)						
D&C Red No.	6 (UNII: 4817	744AI4O)							
Barium Oxide	e (UNII: 7760	3K202B)							
Product Cl									
Color	PINK (dar				Score		2 piece	es	
Shape	OVAL (Fl	lat beveled c	apsule shaped)		Size		11mm		
Flavor					Imprint Code		1;WAR	RFARIN;TA	ARO
Contains									
Dackaging									
Packaging # Item	Code	Daci	kage Description	Ма	relating Start D	ata	M	rkotina	End Date
# Item 1 NDC:51138-			TTLE, PLASTIC	IVId	rketing Start Da	ale	IVIC	irketing	Ellu Date
I NDC.51150-	034-30	50 111 1 00	TILE, FLASTIC						
		•							
Marketin	ıg Infori	mation							
Marketing C	Category	Applicatio	on Number or Monogra	ph Citat	tion Marketin	ıg Star	t Date	Market	ing End Date
-		Applicatio NDA040301	-	ıph Citat	tion Marketin 02/09/2011	-	t Date	Market	ing End Date
-			-	iph Citat		-	t Date	Market	ing End Date
ANDA	A	NDA0 40 30 1	-	iph Citat		-	t Date	Market	ing End Date
ANDA	A	NDA0 40 30 1	-	ph Citat		-	t Date	Market	ing End Date
anda WARFAR	A RIN SOD	NDA0 40 30 1	-	ıph Citat		-	t Date	Market	ing End Date
anda WARFAR	A RIN SOD	NDA0 40 30 1	-	ıph Citat		-	t Date	Market	ing End Date
ANDA WARFAR varfarin sodi	A RIN SOD		-	ph Citat		-	t Date	Market	ing End Date
ANDA WARFAR varfarin sodi Product In	A RIN SOD ium tablet iformation		-						
ANDA WARFAR varfarin sodi Product In Product Typ	A RIN SOD ium tablet oformation				02/09/2011				
ANDA WARFAR varfarin sodi Product In Product Typ	A RIN SOD ium tablet oformation		HUMAN PRESCRIPTION		02/09/2011				
Marketing C ANDA WARFAR warfarin sodi Product In Product Typ Route of Adn	A RIN SOD ium tablet oformation		HUMAN PRESCRIPTION		02/09/2011				
ANDA WARFAR varfarin sodi Product In Product Typ Route of Adm	A RIN SOD ium tablet iformation be ninistration		HUMAN PRESCRIPTION ORAL		02/09/2011				
ANDA WARFAR varfarin sodi Product In Product Typ Route of Adm	A RIN SOD ium tablet iformation be ninistration	NDA040301	HUMAN PRESCRIPTION ORAL		02/09/2011	ce) N	IDC:5113	8-055(ND	C:51672-4028
ANDA WARFAR varfarin sodi Product In Product Typ Route of Adm Active Ingu	A RIN SOD ium tablet iformation re ninistration	DIUM	HUMAN PRESCRIPTION ORAL ety redient Name	DRUG	02/09/2011	rce) N Basi	IDC:5113	8-055(ND	C:51672-4028 Strength
ANDA WARFAR varfarin sodi Product In Product Typ Route of Adm Active Ingu	A RIN SOD ium tablet iformation re ninistration	DIUM	HUMAN PRESCRIPTION ORAL	DRUG	02/09/2011	rce) N Basi	IDC:5113	8-055(ND	C:51672-4028
ANDA WARFAR varfarin sodi Product In Product Typ Route of Adm Active Ingu	A RIN SOD ium tablet iformation re ninistration	DIUM	HUMAN PRESCRIPTION ORAL ety redient Name	DRUG	02/09/2011	rce) N Basi	IDC:5113	8-055(ND	C:51672-4028 Strength
ANDA WARFAR varfarin sodi Product In Product Typ Route of Adn Active Ingi Warfarin Sod	A RIN SOD ium tablet ium tablet iformation re dient/Ac lium (UNII: 6	NDA040301	HUMAN PRESCRIPTION ORAL ety redient Name	DRUG	02/09/2011	rce) N Basi	IDC:5113	8-055(ND	C:51672-4028 Strength
ANDA WARFAR varfarin sodi Product In Product Typ Route of Adn Active Ingi Warfarin Sod	A RIN SOD ium tablet ium tablet iformation re dient/Ac lium (UNII: 6	NDA040301	HUMAN PRESCRIPTION ORAL ety redient Name _) (Warfarin - UNII:5Q7ZV	DRUG	02/09/2011	rce) N Basi	IDC:5113	8-055(ND	C:51672-4028 Strength 2 mg
ANDA WARFAR varfarin sodi Product In Product Typ Route of Adm Active Ingu Warfarin Sod Inactive Ing	A RIN SOD ium tablet ium tablet iformation redient/Ac lium (UNII: 6 gredients	NDA040301	HUMAN PRESCRIPTION ORAL ety redient Name	DRUG	02/09/2011	rce) N Basi	IDC:5113	8-055(ND	C:51672-4028 Strength
ANDA WARFAR varfarin sodi Product In Product Typ Route of Adm Active Ingu	A RIN SOD Jum tablet Iformation Pe ministration redient/Ac lium (UNII: 6 gredients UNII: 082321	NDA040301	HUMAN PRESCRIPTION ORAL ety redient Name L) (Warfarin - UNII:5Q7ZV Ingredient Name	DRUG	02/09/2011	rce) N Basi	IDC:5113	8-055(ND	C:51672-4028 Strengtl 2 mg

FD&C Red No. 40 (UNII: WZB9127XOA) Aluminum Oxide (UNII: LMI2606933)

Product Characteristics

Color		(lavender)			Sco			2 piec		
Shape	OVAL (F	lat beveled ca	ipsule shaped)		Size			11mm		
Flavor Contains					Imp	rint Code		2;WA	RFARIN;TA	ARO
Contains										
Packaging	{									
# Iten	n Code	Pacl	age Description	Ma	ırketir	ng Start D	ate	Ν	larketing	End Date
1 NDC:51138	-055-30	30 in 1 BO	TTLE, PLASTIC							
Marketi	ng Infor	mation								
Marketing	Category	Applicatio	n Number or Monogra	aph Cita	tion	Marketi	ng Sta	rt Date	Market	ing End Date
ANDA	I	ANDA040301				02/09/201	1			
	nformation	ı								
Product Ty	pe		HUMAN PRESCRIPTION	DRUG	Ite m C	ode (Sou	rce)	NDC:5113	38-056(ND	C:51672-4029
Route of Ad	ministration	n	ORAL							
Active Ing	redient/A		0							
		-	redient Name					sis of St	-	Strength
Warfarin So	dium (UNII: 6	5153CWM0CI	.) (Warfarin - UNII:5Q7ZV	/V76EI)			Warfai	rin Sodiur	m	2.5 mg
Inactive I	ngredients	5								
	(7 - 5 - 7 - 7		Ingredient Name						Str	ength
anhydrous la starch, corn			()							
magnesium			30)							
FD&C Blue I										
	No. 10 (UNII:									
Aluminum C										
Product C	haracteris	stics								
Color	GREEN				Sco	re		2 piec	ces	

Color	GREEN	Score	2 pieces
Shape	OVAL (Flat beveled capsule shaped)	Size	11mm
Flavor		Imprint Code	2;WARFARIN;TARO
Contains			

Packaging							
# Item Code	Pac	kage Description	Marketi	ng Start Date	Ma	arketing	End Date
1 NDC:51138-056-30	30 in 1 BC	OTTLE, PLASTIC					
Marketing Inf	ormation						
Marketing Categor	Application	on Number or Monograp	h Citation	Marketing St	art Date	Market	ing End Date
ANDA	ANDA04030	1		02/09/2011			
	et						
warfarin sodium tabl	et	HUMAN PRESCRIPTION D	RUG Item	Code (Source)	NDC:51138	8-057(ND	C:51672-4030
warfarin sodium tabl Product Informa	et t ion	HUMAN PRESCRIPTION D ORAL	RUG Item (Code (Source)	NDC:51138	8-057(ND)	C:51672-4030
Product Type	et t ion		RUG Item	Code (Source)	NDC:51138	8-057(ND)	C:51672-4030
warfarin sodium tabl Product Informa Product Type	et tion tion	ORAL	RUG Item	Code (Source)	NDC:51138	8-057(ND)	C:51672-4030

Ingredient Name	Basis of Strength	Strength
Warfarin Sodium (UNII: 6153CWM0CL) (Warfarin - UNII:5Q7ZVV76EI)	Warfarin Sodium	3 mg

Ingredient Name	Strength
anhydrous lactose (UNII: 3SY5LH9PMK)	
starch, corn (UNII: O8232NY3SJ)	
magnesium stearate (UNII: 70097M6I30)	
FD&C Blue No. 2 (UNII: L06K8R7DQK)	
FD&C Red No. 40 (UNII: WZB9127XOA)	
D&C Yellow No. 10 (UNII: 35SW5USQ3G)	
Aluminum Oxide (UNII: LMI26O6933)	

Product Cha	racteristics		
Color	brown (tan)	Score	2 pieces
Shape	OVAL (Flat beveled capsule shaped)	Size	11mm
Flavor		Imprint Code	3;WARFARIN;TARO
Contains			

Package Description Marketin	g Start Date Marketing End Date
I BOTTLE, PLASTIC	
	•

Marketing Cate	gory A	pplication Number or Monogr	aph Citation	Marketing	Start Date	Market	ing End Dat
ANDA	AN	DA040301		02/09/2011			
WARFARIN		UM					
warfarin sodium	tablet						
Product Infor	mation						
Product Type		HUMAN PRESCRIPTION	N DRUG Item	n Code (Source) NDC:511	38-058(NE	OC:51672-403
Route of Admini	stration	ORAL					
Active Ingred	ient/Acti	ive Moiety					
		Ingredient Name			Basis of St	rength	Strength
Warfarin Sodium	(UNII: 615	3CWM0CL) (Warfarin - UNII:5Q7Z)	VV76EI)	Wa	rfarin Sodiui	m	4 mg
Inactive Ingre	dients						
		Ingredient Name				Str	ength
anhydrous lactos							
starch, corn (UNII							
magnesium steara							
FD&C Blue No. 1	`	,					
Aluminum Oxide	(UNII: LMI	2606933)					
Product Chara	acteristi	CS					
	LUE		Se	core	2 piec	ces	
		beveled capsule shaped)		ize	11mm		
Flavor				nprint Code		.RFARIN;TA	ARO
Contains				•			
Packaging							
# Item Co	de	Package Description	Marke	ting Start Date	e N	larketing	End Date
1 NDC-51120 050	-30	30 in 1 BOTTLE, PLASTIC		0		0	
1 NDC:51138-058-							
I NDC:51138-058-							
	nform	ation					
Marketing I Marketing Cate		ation Application Number or Monogr	aph Citation	Marketing	Start Date	Market	ing End Dat

WARFARIN SODIUM

warfarin sodium tablet

Product In	formation							
Product T yp	e		HUMAN PRESCRIPTION	DRUG Ite	m Code (Source)	NDC:5	51138-059(NI	DC:51672-403
Route of Adn	ninistration		ORAL					
Active Ingr	edient/Ac	tive Moie	ty					
0			edient Name		B	asis of	Strength	Strengt
Warfarin Sod	i um (UNII: 61	153CWM0CL) (Warfarin - UNII:5Q7ZV	V76EI)		farin Soc	-	5 mg
Inactive Ing	gredients							
	,		Ingredient Name				St	rength
nhydrous lad	tose (UNII: 3	SY5LH9PMF	.)					
tarch, corn (U	JNII: 08232N	IY3SJ)						
nagnesium st	earate (UNII	: 70097M6I3	0)					
	6 10 (UNII)	35SW5USQ3	G)					
D&C Yellow N	0.10 (01111							
	,	AII26O6933)						
Aluminum Ox	ide (UNII: LN							
Aluminum Ox D&C Red No. Barium Oxide Product Ch	ide (UNII: LM 5 (UNII: 4817 (UNII: 77603 aracterist	44AI4O) 3K202B) tics			_			
Aluminum Ox D&C Red No. Barium Oxide Product Ch Color	ide (UNII: LM 5 (UNII: 4817 (UNII: 77603 aracterist ORANGE	44AI4O) 3K202B) tics (peach)	nsule shaped)		Score		pieces	
Aluminum Ox D&C Red No. Barium Oxide Product Ch Color Shape	ide (UNII: LM 5 (UNII: 4817 (UNII: 77603 aracterist ORANGE	44AI4O) 3K202B) tics (peach)	psule shaped)	E	Size	111	mm	ARO
D&C Yellow N Aluminum Ox D&C Red No. Barium Oxide Product Ch Color Shape Flavor Contains	ide (UNII: LM 5 (UNII: 4817 (UNII: 77603 aracterist ORANGE	44AI4O) 3K202B) tics (peach)	psule shaped)	E		111		ARO
Aluminum Ox D&C Red No. Barium Oxide Product Ch Color Shape Flavor	ide (UNII: LM 5 (UNII: 4817 (UNII: 77603 aracterist ORANGE	44AI4O) 3K202B) tics (peach)	psule shaped)	E	Size	111	mm	ARO
Aluminum Ox D&C Red No. Barium Oxide Product Ch Color Shape Flavor Contains Packaging	ide (UNII: LM 5 (UNII: 4817 (UNII: 77603 aracterist ORANGE OVAL (Fla	44AI4O) 3K202B) tics (peach) at beveled ca		E	Size	111	mm WARFARIN;T	
Aluminum Ox D&C Red No. Barium Oxide Product Ch Color Shape Flavor Contains Packaging	ide (UNII: LM 5 (UNII: 4817 (UNII: 77603 aracterist ORANGE	44AI4O) 3K202B) tics (peach) at beveled ca	age Description	1	Size	111	mm	
Aluminum Ox D&C Red No. Barium Oxide Product Ch Color Shape Flavor Contains Packaging # Item	ide (UNII: LM 5 (UNII: 4817 (UNII: 77603 aracterist ORANGE OVAL (Fla OVAL (Fla	44AI4O) 3K202B) tics (peach) at beveled ca		1	Size Imprint Code	111	mm WARFARIN;T	
Aluminum Ox D&C Red No. Barium Oxide Product Ch Color Shape Flavor Contains Packaging # Item	ide (UNII: LM 5 (UNII: 4817 (UNII: 77603 aracterist ORANGE OVAL (Fla OVAL (Fla	44AI4O) 3K202B) tics (peach) at beveled ca	age Description	1	Size Imprint Code	111	mm WARFARIN;T	
Aluminum Ox D&C Red No. Barium Oxide Product Ch Color Shape Flavor Contains Packaging	ide (UNII: LM 5 (UNII: 4817 (UNII: 77603 aracteris 0RANGE 0VAL (Fla 0VAL (Fla 59-30	44AI4O) 3K202B) tics (peach) at beveled ca beveled ca 20 in 1 BO	age Description	1	Size Imprint Code	111	mm WARFARIN;T	
Aluminum Ox D&C Red No. Barium Oxide Product Ch Color Shape Flavor Contains Packaging J Item NDC:51138-0	ide (UNII: LM 5 (UNII: 4817 (UNII: 77603 aracterist ORANGE OVAL (Fla 0VAL (Fla 59-30 g Inform	44AI4O) 3K202B) tics (peach) at beveled ca Pack 30 in 1 BO nation	age Description	S Mark	Size Imprint Code eting Start Date	111	mm WARFARIN;T. Marketing	

Route of Administration

ORAL

Active Ingr	e die nt/A	ctive Moi	ety						
Ingredient Name					Basis o	of Strength	Strength		
Warfarin Sodium (UNII: 6153CWM0CL) (Warfarin - UNII:5Q7ZVV76EI)							Warfarin S	odium	6 mg
Inactive Ing	redient	s							
			Ingredient Name					Sti	rength
anhydrous lactose (UNII: 3SY5LH9PMK)									0
starch, corn (U	JNII: 08232	2NY3SJ)							
magnesium stearate (UNII: 70097M6I30)									
D&C Yellow No. 10 (UNII: 35SW5USQ3G)									
FD&C Blue No. 2 (UNII: L06K8R7DQK)									
Aluminum Oxi	i de (UNII: I	LMI2606933)							
Product Ch	aractori	stics							
Color	turquoise				Sco	*0		2 pieces	
	-		psule shaped)					•	
Shape Flavor	OVAL (I					Size		11mm 6;WARFARIN;TARO	
Contains					шпр	rint Code		0,WARFARIN,II	AKO
Contains									
# Item 1 NDC:51138-0			kage Description DTTLE, PLASTIC			ng Start I			g End Date
Marketing	g Infor	mation							
Marketing Ca			n Number or Monogra	ph Cita	tion	Market	ing Start I	Date Marke	ting End Date
ANDA ANDA040301			-			02/09/201	-		8
WARFAR	IN SOI	DIUM							
warfarin sodiu	ım tablet								
Product Inf	ormatio	n							
Product Type			HUMAN PRESCRIPTION	DRUG	Ite m C	Code (Sou	irce) ND	C:51138-061(NI	DC:51672-4034)
Route of Administration			ORAL						
Active Ingr	e die nt/A	ctive Moi	ety						
					of Strength	Strength			
Warfarin Sodi	Warfarin Sodium (UNII: 6153CWM0CL) (Warfarin - UNII:5Q)			V76EI)			Warfarin S	_	7.5 mg

Ingredient Name							Strength	
anhydi	rous lactose	(UNII: 3	SY5LH9PMK)					
starch,	, corn (UNII:	08232N	Y3SJ)					
magne	esium steara	te (UNII:	:70097M6I30)					
D&C Y	Yellow No. 10	(UNII: 3	35SW5USQ3G)					
Alumiı	num Oxide (UNII: LM	112606933)					
n 1								
	uct Chara		tics	-		- ·		
Color		YELLOW			re	2 piec	es	
Chama	· · · · · · · · · · · · · · · · · · ·	OVAL (Flat beveled capsule shaped)			e	11mm		
Shape			ti beveleti capsule shapeti)					
Flavor	r	AL (Fia			orint Code	7;WAI	RFARIN;TARO	
-	r					7;WAI	RFARIN;TARO	
Flavor	r					7;WAI	RFARIN;TARO	
Flavor Contai	r	AL (Fi				7;WAI	RFARIN;TARO	
Flavor Contai	r ins		Package Description	Imp			RFARIN;TARO	
Flavor Contai Packa #	r ins aging	e		Imp	orint Code			
Flavor Contai Packa #	r ins aging Item Coo	e	Package Description	Imp	orint Code			
Flavor Contai Packa #	r ins aging Item Coo	e	Package Description	Imp	orint Code			
Flavor Contai Packa # 1 NDC	r ins aging Item Coc C:51138-061-3	e 0	Package Description 30 in 1 BOTTLE, PLASTIC	Imp	orint Code			
Flavor Contai Packa # 1 NDC	r ins aging Item Coc C:51138-061-3 'keting I	e o nforn	Package Description 30 in 1 BOTTLE, PLASTIC nation	Imp Marketin	orint Code ng Start Date	M	arketing End Date	
Flavor Contai Packa # 1 NDC	r ins aging Item Coo C:51138-061-3 'keting I seting Categ	e 0 nform ory	Package Description 30 in 1 BOTTLE, PLASTIC	Imp Marketin	orint Code	M		

warfarin sodium tablet

HUMAN PRESCRIPTION DRUG	Item Code (Sou	rce) NDC:5	1138-062(ND0	C:51672-4035)	
ORAL					
etv					
redient Name		Basis of	Strength	Strength	
Ingredient Name			Stre	ength	
K)					
30)					
	ORAL ety redient Name .) (Warfarin - UNII:5Q7ZVV76EI) Ingredient Name <	ORAL ety redient Name .) (Warfarin - UNII:5Q7ZVV76EI) Ingredient Name	ORAL ety redient Name Basis of S () (Warfarin - UNII:5Q7ZVV76EI) Warfarin Sod Ingredient Name ()	ORAL ORAL tety redient Name Basis of Strength U) (Warfarin - UNII:5Q7ZVV76EI) Warfarin Sodium Ingredient Name Stree	

Product Cha	racterist	ics				
Color	WHITE		Sco	ore	2 pieces	5
Shape	OVAL (Flat	t beveled capsule shaped)	Siz	ze	11mm	
Flavor				print Code	e 10;WARFARIN;TARO	
Contains						
Packaging						
# Item (Code	Package Description	Market	ting Start Date	Ma	arketing End Date
1 NDC:51138-06	52-30	30 in 1 BOTTLE, PLASTIC				
Marketing	g Inform	nation				
Marketing Ca	tegory A	Application Number or Monogra	ph Citation	Marketing Star	t Date	Marketing End Date
ANDA	AN	ANDA040301		02/09/2011		

Labeler - Med-Health Pharma, LLC (962603812)

Establishment						
Name	Address	ID/FEI	Business Operations			
Med-Health Pharma, LLC		962603812	repack			

Revised: 1/2012

Med-Health Pharma, LLC